The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Kostenko E.V.

Poliklinika vosstanovitel'nogo lecheniia #7;
Kafedra nevrologii i neĭrokhirurgii Rossiĭskogo gosudarstvennogo meditsinskogo universiteta;
Kafedra nevrologii Moskovskogo gosudarstvennogo mediko-stomatologicheskogo universiteta

Influence chronopharmacology therapy methionine (melaxen) on the dynamics of sleep disturbance, cognitive and emotional disorders, brain-derived neurotrophic factor (BDNF) in patients with cerebral stroke in the early and late recovery periods

Authors:

Kostenko E.V.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2017;117(3): 56‑64

DOI: 10.17116/jnevro20171173156-64

Views: 3097

Downloaded: 55

Download PDF (RU)
Contact the author
Table of contents

To cite this article:

Kostenko EV. Influence chronopharmacology therapy methionine (melaxen) on the dynamics of sleep disturbance, cognitive and emotional disorders, brain-derived neurotrophic factor (BDNF) in patients with cerebral stroke in the early and late recovery periods. S.S. Korsakov Journal of Neurology and Psychiatry. 2017;117(3):56‑64. (In Russ.)
https://doi.org/10.17116/jnevro20171173156-64

 
МСФ на ЯМ
Close metadata
Recommended articles:
The asso­ciation of poly­morphisms of the sero­tonin transporter gene SLC6A4 with depression. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(2):135-139
The effect of inso­mnia on mild cognitive impairment in patients with vascular risks: resu­lts of a three-year longitudinal study. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(3-2):30-36
Cere­brolysin as an early add-on to repe­rfusion therapy: hete­rogeneous treatment effect analysis in ischemic stroke patients with varying risk of hemo­rrhagic transformation. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(3-2):55-66
Effi­cacy of Mexi­dol in combination with cere­bral reva­scularization in the treatment of ischemic stroke. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(3-2):67-74
A perspective on the application of CRISPR/CAS9 genome editing system to study of mole­cular-genetic basis of mental diso­rders. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(3):27-33
Vali­dation of screening method based on EEG analysis for the risk asse­ssment of psychiatric and beha­vioral diso­rders: a pilot study. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(3):88-96
A clinical case of the new-onset bipo­lar affe­ctive diso­rder in the postcovid period. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(3):125-129
Expe­rience of exoskeletal reha­bilitation of a patient with supe­rior flaccid mono­paresis caused by a gunshot wound after neurosurgical reco­nstruction of the branches of the brachial plexus. Russian Journal of Operative Surgery and Clinical Anatomy. 2024;(1):35-41
Factors of physical acti­vity in children after congenital heart disease repair. Russian Journal of Cardiology and Cardiovascular Surgery. 2024;(2):158-163
Inte­rnational Classification of Health Inte­rventions of World Health Orga­nization as the basis for a new nome­nclature of medi­cal reha­bilitation services. Problems of Balneology, Physiotherapy and Exercise Therapy. 2024;(2):5-11

Objective. To study the efficacy of melaxen on the dynamics of sleep disturbance, cognitive and emotional disorders, BDNF and the level of secretion of melatonin (6-SOMT) in patients with stroke in the early and late recovery phase. Material and methods. One hundred and ten patients in the rehabilitation period of stroke (mean age of 58.4±6.4 years), including 60 patients in the early recovery phase (group 1) and 50 patients in the late phase (group 2), were studied. Patients received melaxen in dose of 3 mg/day for 3 months along with standard treatment. The efficacy of therapy was assessed by the dynamics of sleep disorders, emotional status, dynamics of serum BDNF levels, 6-SOMT concentration in the urine. Results and conclusion. The study has demonstrated the high efficacy of melaxen in the rehabilitation of patients in early and late recovery phase of stroke. The drug significantly increased the BDNF level that correlated with improved sleep, emotional status, quality of life of patients.

Keywords:

stroke
medical rehabilitation
melaxen
sleep disturbance
depression
brain-derived neurotrophic factor BDNF

Authors:

Kostenko E.V.

Poliklinika vosstanovitel'nogo lecheniia #7;
Kafedra nevrologii i neĭrokhirurgii Rossiĭskogo gosudarstvennogo meditsinskogo universiteta;
Kafedra nevrologii Moskovskogo gosudarstvennogo mediko-stomatologicheskogo universiteta

List of references:

  1. Levin YaI. Melatonin (melaksen) v terapii insomnia. Russ med zhurn. 2005;13(7):498-500. (In Russ.).
  2. Mayer G, Jennum P, Riemann D, Dauvilliers Y. Insomnia in central neurologic diseases — Occurrence and management. Sleep Medicine Reviews. 2011;15(6):369-378. doi: 10.1016/j.smrv.2011.01.005
  3. Zimina SV. Dorsal'nye yadra shva i sezonnye affektivnye rasstroistva. Psikhiatriya. 2009;1:67-74. (In Russ.).
  4. Slesarev SM. Epifizarnaya I tkanevaya regulyatsii vremennoi organizatsii proliferatsii obnovlyayushchikhsya tkanei: Dis. ... dokt. biol. nauk. M. 2009. (In Russ.). Ssylka aktivnana 12.12.2017. Dostupnopo: http://www.slesarev.ru/downloads/disser.pdf
  5. Mazzoccoli G, Giuliani A, Carughi S, De CataA., PuzzolanteF, La ViolaM, UrbanoN, Tarquini R. The hypothalamic-pituitary-thyroid axis and melatonin in humans: possible interactions in the control of body temperature. Neuro Endocrinol Lett. 2004;25(5):368-372.
  6. Turner P, Mainster M. Circadian photoreception: ageing and the eye's important role in systemic health. British Journal of Ophthalmology. 2008;92(11):1439-1444. doi: 10.1136/bjo.2008.141747
  7. Danilenko KV. Rol' svetovykh vozdeistvii v regulyatsii sutochnoi, mesyachnoi I godovoi tsiklichnosti u cheloveka: Dis. ... dokt. med. nauk. Novosibirsk. 2009. (In Russ.). Dostupno po http://www.danilenko.ru/downloads/disser.pdf
  8. Mendel' VE, Mendel' OI. Melatonin: rol' v organizme i terapevticheskie vozmozhnosti. Opyt primeneniya preparata Melaksen v rossiiskoi meditsinskoi praktike. RMZh. 2010; 6:336-342. (In Russ.). doi: 10.1136/bmj.c4879
  9. Kostoglou-Athanassiou I. Therapeutic applications of melatonin. Therapeutic Advances in Endocrinology and Metabolism. 2013;4(1):13-24. doi: 10.1177/2042018813476084
  10. Zasseeva AL. Patofiziologicheskoe obosnovanie primeneniya metodov khronoterapii u bol'nykh s razlichnymi formami neirotsirkulyatornoi distonii: Dis. ... kand. med. nauk. Vladikavkaz. 2009. (In Russ.). Ssylka aktivnana 10.02.2017. Dostupnopo: http://www.zasseeva.ru/downloads/disser.pdf
  11. Yakhno NN. Otchet o klinicheskoi effektivnosti preparata «MELAKSEN» firmy Unipharm-USA (SShA) pri lechenii insomnii. Lechashchii vrach. 1999;10:34-37. (In Russ.).
  12. Tordjman S, Chokron S, Delorme R, Charrier A, Bellissant E, Jaafari N, Fougerou C. Melatonin: pharmacology, functions and therapeutic benefits.Curr Neuropharmacol. 2016;14. doi: 10.2174/1570159X14666161228122115
  13. Peacock B, Scheiderer D, Kellermann G. Biomolecular aspects of depression: A retrospective analysis. Comprehensive Psychiatry. 2017;73:168-180. doi: 10.1016/j.comppsych.2016.11.002
  14. Tan D, Manchester L, Qin L, Reiter R. Melatonin: A Mitochondrial Targeting Molecule Involving Mitochondrial Protection and Dynamics. International Journal of Molecular Sciences. 2016;17(12):2124. doi: 10.3390/ijms17122124
  15. Ghareghani M, Sadeghi H, Zibara K, Danaei N, Azari H, Ghanbari A. Melatonin Increases Oligodendrocyte Differentiation in Cultured Neural Stem Cells. Cellular and Molecular Neurobiology. 2016. doi: 10.1007/s10571-016-0450-4
  16. Yu X, Li Z, Zheng H, Ho J, Chan M, Wu W. Protective roles of melatonin in central nervous system diseases by regulation of neural stem cells. Cell Proliferation. 2016. doi: 10.1111/cpr.12323
  17. Romero A, Ramos E, Patiño P, Oset-Gasque M, López-Muñoz F, Marco-Contelles J. Melatonin and Nitrones As Potential Therapeutic Agents for Stroke. Frontiers in Aging Neuroscience. 2016;8:281. doi: 10.3389/fnagi.2016.00281
  18. Pandi-Perumal S, Ba Hammam A, Brown G, Spence D, Bharti V, Kaur C, Hardeland R, Cardinali D. Melatonin Antioxidative Defense: Therapeutical Implications for Aging and Neurodegenerative Processes. Neurotoxicity Research. 2012;23(3):267-300. doi: 10.1007/s12640-012-9337-4
  19. Kostenko EV, Petrova LV. Effektivnost' korrektsii narushenii sna, kognitivnykh i emotsional'nykh rasstroistv preparatom melaksen® s uchetom urovnya sekretsii melatonina u patsientov s tserebrovaskulyarnymi zabolevaniyami. Consilium Medicum (pril. Nevrologiya. Revmatologiya). 2015;1:38-46. (In Russ.).
  20. Kostenko EV, Bobyreva SN. Vliyanie korrektsii narushenii sna na effektivnost' reabilitatsionnykh meropriyatii u patsientov, perenesshikh mozgovoi insul't. Consilium Medicum. 2016;18(9):49-55. (In Russ.).
  21. Kostenko E, Petrova L, Eneeva M, Kamchatnov P. Sleep disorders and circadian rhythms in diseases of the cardiovascular system. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2015;115(3):30-37. (In Russ). doi: 10.17116/jnevro20151153130-36
  22. Vinogradov OI, Ivanova DS, Davidov NP, Kuznetsov A.N Melatonin in the correction of sleep in post-stroke patients. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2015;115(6):86. (In Russ). doi: 10.17116/jnevro20151156186-89
  23. Sunami E, Usuda K, Nishiyama Y, Otori T, Katsura K, Katayama Y. A Preliminary Study of Fluvoxamine Maleate on Depressive State and Serum Melatonin Levels in Patients after Cerebral Infarction. Internal Medicine. 2012;51(10):1187-1193. doi: 10.2169/internalmedicine.51.6699
  24. Domzał TM, Kaca-Oryńska M, Zaleski P. Melatonin in sleep rhythm disorders after cerebral stroke. Pol Merkur Lekarski. 2000;8(48):411-412.
  25. Groves J. Is it time to reassess the BDNF hypothesis of depression? Molecular Psychiatry. 2007;12(12):1079-1088. doi: 10.1038/sj.mp.4002075
  26. Kuipers SD, Bramham CR. Brain-derived neurotrophic factor mechanisms and function in adult synaptic plasticity: new insights and implications for therapy. Curr Opin Drug Discov Devel. 2006;9:580-586.
  27. Robinson RC, Radziejewski C, Stuart Dl, Jones EY. Structure of the brain-derived neurotrophic factor heurotrophin 3 heterodimer. Biochemistry. 1995;34:4139-4146.
  28. Fujimura H, Altar CA, Chen R, Nakamura T, Nakahashi T, KambayashiJ, Sun B, Tandon NN. Brain-derived neurotrophic factor is stored in human platelets and released by agonist stimulation. Thromb Haemost. 2002;87:728-734.
  29. Pearse AG. The common peptides and the cytochemistry of their cells of origin. Basic Appl Histochem. 1980;24:63-73.
  30. Barde YA, Edgar D, Thoenen H. New neurotrophic factors. Annu Rev Physiol. 1985;45:601-612.
  31. Kauer-Sant'anna M, Yatham LN, Tramontina J, Weyne F, Cereser KM, Gazalle FK, Andreazza AC, Santin A, Quevedo J, Izquierdo I, Kapczinski F. Emotional memory in bipolar disorder. The British Journal of Psychiatry. 2008;192(6):458-463. doi: 10.1192/bjp.bp.107.040295
  32. Cirelli C, Tononi G. Differential expression of plasticity related genes in waking and sleep and their regulation by the noradrenergic system. J Neurosci. 2000;20(24):9187-9194.
  33. Ploughman M, Windle V, MacLellan C, White N, Dore J, Corbett D. Brain-Derived Neurotrophic Factor Contributes to Recovery of Skilled Reaching After Focal Ischemia in Rats. Stroke. 2009;40(4):1490-1495. doi: 10.1161/strokeaha.108.531806
  34. Ramos-Cejudo J, Gutierrez-Fernandez M, Otero-Ortega L, Rodríguez-Frutos B, Blanca Fuentes B, Vallejo-Cremades MT, Hernanz TN, Cerdán S.Brain-Derived Neurotrophic Factor Administration Mediated Oligodendrocyte Differentiation and Myelin Formation in Subcortical Ischemic Stroke. Stroke. 2014;46(1):221-228. doi: 10.1161/strokeaha.114.006692
  35. Berretta A, Tzeng Y, Clarkson A. Post-stroke recovery: the role of activity-dependent release of brain-derived neurotrophic factor. Expert Review of Neurotherapeutics. 2014;14(11):1335-1344. doi: 10.1586/14737175.2014.969242
  36. Sun J, Ke Z, Yip S, Hu X, Zheng X, Tong K. Gradually Increased Training Intensity Benefits Rehabilitation Outcome after Stroke by BDNF Upregulation and Stress Suppression. BioMed Research International. 2014;2014:1-8. doi: 10.1155/2014/925762
  37. Chen J, Zhang C, Jiang H, Li Y, Zhang L, Robin A, Katakowski M, Lu M, Chopp M. Atorvastatin induction of VEGF and BDNF promotes brain plasticity after stroke in mice. Journal of Cerebral Blood Flow & Metabolism. 2005;25(2):281-290. doi: 10.1038/sj.jcbfm.9600034
  38. Kulesh AA, Shestakov VV. Khronobiologicheskie pokazateli, kognitivnyi, emotsional'nyi status I kachestvo sna v ostrom periode insul'ta. Zhurnal nevrol i psikhiatr im. S.S. Korsakova. 2013;113:4:24-28. (In Russ).

Close metadata

Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.